TF and neoplasm: DELFI-TF was similar in overall performance for non-invasive monitoring to a mutation-based MAF approach using known tissue-informed variants, but the ability to detect samples with independently validated ctDNA that was not detected by ddPCR suggests that DELFI-TF may be more accurate at capturing overall tumor burden.